Want to see FENC full AI Analyst Report?
FENC Stock Chart & Stats
$6.79
-$0.02(-0.33%)
At close: 4:00 PM EST
$6.79
-$0.02(-0.33%)
Day’s Range― - ―
52-Week Range$5.65 - $11.31
Previous Close$6.08
Volume58.66K
Average Volume (3M)292.22K
Market Cap
$356.05M
Enterprise Value$216.47M
Total Cash (Recent Filing)$40.18M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 06, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.31
Shares Outstanding34,737,030
10 Day Avg. Volume270,894
30 Day Avg. Volume292,223
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)6.28
Price to Sales (P/S)4.93
P/FCF Ratio-17.64
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue4.24
Enterprise Value/Gross Profit4.60
Enterprise Value/Ebitda-32.44
Forecast
1Y Price Target
$15.50Price Target Upside128.28% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.26
Revenue Forecast (FY)$68.48M
Bulls Say, Bears Say
Bulls Say
High Gross Margins And Revenue ScaleSustained ~92% gross margins on ~$51M TTM revenue indicate durable product economics for PEDMARK. High margins support scalable profitability as volume grows, permit reinvestment into commercial activities, and reduce dependence on pricing levers, strengthening long-term margin sustainability.
Commercial Traction Via HEARS Hub And Strong AdherenceHEARS hub operational gains (48% QoQ infusion growth, ~80% conversion/adherence) reflect an efficient care-delivery model that captures eligible patients and converts prescriptions into sustained use. This durable channel strength supports predictable revenue cadence and scales commercial ROI over time.
De-risked Balance Sheet With Zero DebtZero debt and meaningful equity provide financial flexibility to fund commercialization and absorb cash seasonality without immediate refinancing pressure. The cleaner capital structure reduces bankruptcy risk and allows management to prioritize growth investments and potential partnering opportunities.
Bears Say
Persistent Operating Cash BurnOngoing negative operating and free cash flow (~-$7.9M TTM) means the business is not yet self-funding; sustained cash burn increases reliance on existing cash, milestone receipts or capital markets. This constrains optionality and elevates funding risk if revenue ramps slow or expenses rise.
Front-loaded, Higher 2026 Operating Expense GuidanceManagement's guidance for ~$50M cash OpEx, front-loaded into H1, raises near-term execution and liquidity pressure. If commercial productivity or uptake lags, hefty fixed spending could deepen losses and worsen cash burn before revenue catches up, increasing operational risk.
Partner Execution Risk And Missed Milestone (Norgine)A missed Norgine milestone underscores execution risk with international partners and delays expected non-U.S. cash inflows and royalty diversification. Reliance on partner commercialization timelines magnifies single-product concentration and could postpone meaningful non-U.S. revenue contributions.
Fennec Pharmaceuticals News
FENC FAQ
What was Fennec Pharmaceuticals’s price range in the past 12 months?
Fennec Pharmaceuticals lowest stock price was $5.65 and its highest was $11.31 in the past 12 months.
What is Fennec Pharmaceuticals’s market cap?
Fennec Pharmaceuticals’s market cap is $356.05M.
When is Fennec Pharmaceuticals’s upcoming earnings report date?
Fennec Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 27 days.
How were Fennec Pharmaceuticals’s earnings last quarter?
Fennec Pharmaceuticals released its earnings results on May 14, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.044 by $0.054.
Is Fennec Pharmaceuticals overvalued?
According to Wall Street analysts Fennec Pharmaceuticals’s price is currently Undervalued.
Does Fennec Pharmaceuticals pay dividends?
Fennec Pharmaceuticals does not currently pay dividends.
What is Fennec Pharmaceuticals’s EPS estimate?
Fennec Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does Fennec Pharmaceuticals have?
Fennec Pharmaceuticals has 34,737,030 shares outstanding.
What happened to Fennec Pharmaceuticals’s price movement after its last earnings report?
Fennec Pharmaceuticals reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.044. Following the earnings report the stock price went up 36.484%.
Which hedge fund is a major shareholder of Fennec Pharmaceuticals?
Currently, no hedge funds are holding shares in FENC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fennec Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (128.28% Upside)
$15.50 (128.28% Upside)
Blogger Sentiment
Bullish
FENC Sentiment 70%
Sector Average 69%
Sector Average 69%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 13.8%
Last 30 Days ▲ 10.3%
Last 30 Days ▲ 10.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
17.81%
12-Months-Change
Fundamentals
Return on Equity
-55.13%
Trailing 12-Months
Asset Growth
54.78%
Trailing 12-Months
Company Description
Fennec Pharmaceuticals
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
FENC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple material commercial and clinical positives: strong top-line acceleration (+73% YoY), meaningful operational traction from the Fennec HEARS hub (48% QoQ infusion increase, 80% conversion and adherence), expanded commercial reach (prescriber targets expanded from ~1,300 to >5,000) and growing clinical momentum via ISTs and ASCO visibility. Counterbalancing these positives are higher near-term operating expenses (~$14M in Q1, ~$50M expected for 2026 with front-loaded spend), some near-term cash seasonality with Q2 expected to be lower than Q1, and a missed German milestone from partner Norgine. Overall, the highlights and catalysts materially outweigh the lowlights, with management emphasizing that cash plus projected revenues should fund operations and that commercial investments are already showing early returns.View all FENC earnings summariesFENC Stock 12 Month Forecast
Average Price Target
$15.50
▲(128.28% Upside)
Technical Analysis
Satellos Bioscience
―
Helix BioPharma
―
―
Eupraxia Pharmaceuticals
―
ME Therapeutics Holdings, Inc.
―
Ownership Overview
10.31% Insiders
4.76% Mutual Funds
― Other Institutional Investors
78.39% Public Companies and
Individual Investors